OncoMatch/Clinical Trials/NCT06406556
Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL
Is NCT06406556 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pegaspargase combined with concurrent radiotherapy. for extranodal nk/t-cell lymphoma.
Treatment: Pegaspargase combined with concurrent radiotherapy. — The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of concurrent chemoradiotherapy by using single-drug pegaspargase for patients with ENKTL in stage IE to IIE.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IE, IIE
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiotherapy
Exception: within 4 weeks before treatment
No radiotherapy or hormone drugs were received within 4 weeks before treatment
Cannot have received: hormonal therapy
Exception: within 4 weeks before treatment
No radiotherapy or hormone drugs were received within 4 weeks before treatment
Lab requirements
Blood counts
WBC ≥ 3 × 10^9/L, NE ≥ 1.5 × 10^9/L, PLT ≥ 100 × 10^9/L; Serum fibrinogen level ≥ 1.0g/L
Kidney function
Serum creatinine ≤ 1.5mg/dL, creatinine clearance rate ≥ 50mL/min
Liver function
ALT, AST ≤ 3 × ULN; total bilirubin ≤ 2 × ULN
WBC≥ 3 × 10^9 / L, NE ≥ 1.5 × 10^9 / L, PLT ≥ 100 × 10^9 / L ; Serum creatinine ≤ 1.5mg / dL, creatinine clearance rate ≥ 50mL / min ; ALT, AST ≤ 3 × ULN ( normal upper limit ) ; total bilirubin ≤ 2 × ULN ; Serum fibrinogen level ≥ 1.0g / L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify